These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists. Grenald SA; Young MA; Wang Y; Ossipov MH; Ibrahim MM; Largent-Milnes TM; Vanderah TW Neuropharmacology; 2017 Apr; 116():59-70. PubMed ID: 28007501 [TBL] [Abstract][Full Text] [Related]
6. Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats. Datta U; Kelley LK; Middleton JW; Gilpin NW Psychopharmacology (Berl); 2020 Dec; 237(12):3729-3739. PubMed ID: 32857187 [TBL] [Abstract][Full Text] [Related]
7. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice. Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803 [TBL] [Abstract][Full Text] [Related]
8. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies. Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770 [TBL] [Abstract][Full Text] [Related]
9. Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain. Yuill MB; Hale DE; Guindon J; Morgan DJ Mol Pain; 2017; 13():1744806917728227. PubMed ID: 28879802 [TBL] [Abstract][Full Text] [Related]
11. Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine. Imam MZ; Kuo A; Ghassabian S; Cai Y; Qin Y; Li T; Smith MT Eur J Pharmacol; 2020 Mar; 871():172918. PubMed ID: 31958457 [TBL] [Abstract][Full Text] [Related]
12. Reinforcing effects of opioid/cannabinoid mixtures in rhesus monkeys responding under a food/drug choice procedure. Maguire DR; France CP Psychopharmacology (Berl); 2018 Aug; 235(8):2357-2365. PubMed ID: 29860612 [TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154 [TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of cannabinoid ligand-induced modulations in intracellular Ca Xia KK; Shen JX; Huang ZB; Song HM; Gao M; Chen DJ; Zhang SJ; Wu J Acta Pharmacol Sin; 2019 Mar; 40(3):410-417. PubMed ID: 30202013 [TBL] [Abstract][Full Text] [Related]
16. Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis. Porter RF; Szczesniak AM; Toguri JT; Gebremeskel S; Johnston B; Lehmann C; Fingerle J; Rothenhäusler B; Perret C; Rogers-Evans M; Kimbara A; Nettekoven M; Guba W; Grether U; Ullmer C; Kelly MEM Molecules; 2019 Sep; 24(18):. PubMed ID: 31540271 [TBL] [Abstract][Full Text] [Related]
17. Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects. Hu SJ; Cheng G; Zhou H; Zhang Q; Zhang QL; Wang Y; Shen Y; Lian CX; Ma XQ; Zhang QY; Qin LP Molecules; 2022 Jan; 27(3):. PubMed ID: 35163968 [TBL] [Abstract][Full Text] [Related]
18. ß-arrestin 2 germline knockout does not attenuate opioid respiratory depression. Bachmutsky I; Wei XP; Durand A; Yackle K Elife; 2021 May; 10():. PubMed ID: 34002697 [TBL] [Abstract][Full Text] [Related]
19. Slowly Signaling G Protein-Biased CB Lin X; Dhopeshwarkar AS; Huibregtse M; Mackie K; Hohmann AG Mol Pharmacol; 2018 Feb; 93(2):49-62. PubMed ID: 29192123 [TBL] [Abstract][Full Text] [Related]
20. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands. Davis MP Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]